Vestmark Advisory Solutions Inc. Raises Stake in Amgen Inc. $AMGN

Vestmark Advisory Solutions Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 373.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,842 shares of the medical research company’s stock after purchasing an additional 3,819 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Amgen were worth $1,352,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Aspect Partners LLC grew its stake in Amgen by 70.8% in the 2nd quarter. Aspect Partners LLC now owns 987 shares of the medical research company’s stock worth $276,000 after acquiring an additional 409 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in shares of Amgen by 47.0% in the second quarter. Sterling Capital Management LLC now owns 39,452 shares of the medical research company’s stock valued at $11,015,000 after purchasing an additional 12,610 shares during the period. Nvwm LLC boosted its holdings in shares of Amgen by 893.3% in the second quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 134 shares during the period. Walkner Condon Financial Advisors LLC grew its stake in Amgen by 8.4% in the second quarter. Walkner Condon Financial Advisors LLC now owns 933 shares of the medical research company’s stock worth $261,000 after purchasing an additional 72 shares in the last quarter. Finally, Ipsen Advisor Group LLC grew its stake in Amgen by 4.5% in the second quarter. Ipsen Advisor Group LLC now owns 2,172 shares of the medical research company’s stock worth $606,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.76% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the subject of several research reports. UBS Group lowered their target price on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Wells Fargo & Company upped their price objective on shares of Amgen from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. The Goldman Sachs Group dropped their target price on shares of Amgen from $405.00 to $400.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Guggenheim raised their target price on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Finally, DZ Bank upped their price target on shares of Amgen from $335.00 to $364.00 in a research report on Monday. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $311.74.

Amgen Stock Performance

AMGN stock opened at $323.66 on Tuesday. Amgen Inc. has a one year low of $253.30 and a one year high of $335.88. The firm has a market cap of $174.28 billion, a price-to-earnings ratio of 26.46, a PEG ratio of 2.61 and a beta of 0.45. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a 50-day simple moving average of $290.66 and a two-hundred day simple moving average of $288.96.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the previous year, the firm earned $5.58 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio is currently 73.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.